ArticleOcular oncology and pathology2026
Unilateral Glaucoma as a Clinical Indicator of Iris and Ciliary Body Melanoma.
Article in Ocular oncology and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Iris and ciliary body melanomas are rare but potentially life-threatening tumors that are difficult to distinguish from benign nevi. Earlier diagnosis improves outcomes, but reliable clinical indicators are limited. Glaucoma has been observed in conjunction with iris or ciliary body melanoma, but its prevalence and clinical significance at a population level are not well established. Our objective was to determine the prevalence of glaucoma in iris and ciliary body melanoma compared with nevus and to assess whether unilateral glaucoma may serve as a diagnostic indicator of melanoma. Methods: This retrospective cohort study used the IBM MarketScan Research Database, which contains de-identified longitudinal healthcare claims data from commercially insured patients in the USA. Patients with iris or ciliary body melanoma or nevus were identified by International Classification of Diseases, Tenth Revision (ICD-10) diagnostic codes. Outcomes included the prevalence of glaucoma prior to treatment in melanoma versus nevus, age-stratified prevalence of glaucoma, and rates of glaucoma surgery. Odds ratios (ORs) with 95% CIs were calculated to compare groups. Results: A total of 17,978 patients were included (112 with melanoma, 17,866 with nevus). Glaucoma prevalence prior to treatment was significantly higher in the melanoma cohort than nevus cohort (11.6% vs. 1.3%; OR: 10.1; 95% CI: 5.1-18.4; Conclusion: Unilateral glaucoma is significantly more common in eyes with iris and ciliary body melanoma than in those with iris and ciliary body nevus in this claims-based cohort, and melanoma patients are more likely to require surgical management. Unilateral glaucoma may serve as an important early clinical indicator of melanoma, although further clinical correlation is necessary. Incorporating glaucoma status into diagnostic criteria could improve recognition, prompt referral and biopsy, and reduce delays in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.